Copyright ©The Author(s) 2019.
World J Gastroenterol. Aug 7, 2019; 25(29): 3897-3919
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3897
Table 3 Recommended treatment regimens for hepatitis C virus GT1 infection
Recommendation categoryTreatment option/sTreatment regimens
PreferredLDV + SOF ± RBVLDV + SOF for 12 wk
In treatment-naïve patients having HCV RNA < 6 million IU/mL in whom cirrhosis has been conclusively ruled out by transient elastography (FibroScan) or biopsy: LDV + SOF for 8 wk
In treatment-experienced cirrhotic patients/patients with decompensated liver disease/postliver transplant patients: LDV + SOF + RBV for 12 wk (or) LDV + SOF for 24 wk if RBV is ineligible
AlternativeSOF + DCV ± RBVSOF + DCV for 12 wk (addition of RBV may be considered if cirrhosis has not been conclusively ruled out)
In patients with compensated cirrhosis: SOF + DCV ± weight-based RBV for 24 wk
In patients with decompensated cirrhosis: SOF + DCV + RBV for 12 wk (or) SOF + DCV for 24 wk if RBV is ineligible
Not recommendedDue to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.